OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 523 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... November 22, 2022 Woman Who Died For 27 Minutes Shares Haunting Message When Revived August 12, 2019 “My Heart Will Always Hurt”: How I Honor My Childhood Best... April 26, 2022 Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies July 10, 2019 Load more HOT NEWS No Glucose? Pancreatic Cancer May Have a Ready Energy Alternative Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... EMA Recommends Granting a Marketing Authorisation for Tepotinib Health inequalities: Why do people smoke if they know it’s bad...
